It is essential to have information on the disease burden of lung cancer at an individual level throughout the life; however, few such results have been reported. Thus, this study aimed to assess the lifetime disease burden in patients with lung cancer by assessing various factors, such as survival, years of life lost (YLL) and medical expenditure in South Korea based on real-world data and extrapolation. Newly diagnosed lung cancer patients (n = 2919) in 2004–2010 were selected and observed until the end of 2015 using nationwide reimbursement claim database. The patients were categorised into the Surgery group, Chemo and/or Radiotherapy group (CTx/RTx), and Surgery+CTx/RTx according to their treatment modality. Age- and sex-matched control subjects were selected from among general population using the life table. The survival and cost data after diagnosis were analysed by a semi-parametric method, the Kaplan–Meier analysis for the first 100 months and rolling extrapolation algorithm for 101–300 months. YLL were derived from the difference in survival between patients and controls. Lifetime estimates (standard error) were 4.5 (0.2) years for patients and 14.5 (0.1) years for controls and the derived YLL duration was 10.0 (0.2) years. Lifetime survival years showed the following trend: Surgery (14.2 years) > Surgery+CTx/RTx (8.5 years) > CTx/RTx group (3.0 years), and YLL were increased as lifetime survival years decreased (2.3, 8.7, 12.2 years, respectively). The mean lifetime medical cost was estimated at 30,857 USD/patient. Patients in the Surgery group paid higher treatment cost in first year after diagnosis, but the overall mean cost per year was lower at 4359 USD compared with 7075USD of Surgery+CTx/RTx or 7626USD of CTx/RTx group. Lung cancer has resulted in about 10 years of life lost in overall patients. The losses were associated with treatment modality, and the results indicated that diagnosing lung cancer in patients with low stage disease eligible for surgery is beneficial for reducing disease burden in terms of survival and treatment cost per year throughout the life.

中文翻译：

---

肺癌的终生生存率和医疗费用：韩国的半参数估算。

一生中要获得有关个体肺癌水平的信息，这一点至关重要。但是，几乎没有报道这样的结果。因此，本研究旨在通过评估现实生活中的数据和推断，通过评估各种因素，例如生存率，生命损失年限（YLL）和韩国的医疗费用，来评估肺癌患者的终生疾病负担。选择2004-2010年新诊断的肺癌患者（n = 2919），并使用全国报销索赔数据库进行观察直至2015年底。根据治疗方式将患者分为手术组，化疗和/或放疗组（CTx / RTx）和手术+ CTx / RTx。使用寿命表从一般人群中选择年龄和性别匹配的对照对象。诊断后的生存率和成本数据采用半参数方法进行分析，前100个月采用Kaplan-Meier分析，101-300个月采用滚动外推算法。YLL来自患者和对照组之间的生存差异。患者的终生估计（标准误）为4.5（0.2）年，对照组为14.5（0.1）年，得出的YLL持续时间为10.0（0.2）年。终生生存期呈以下趋势：手术（14.2年）>手术+ CTx / RTx组（8.5年）> CTx / RTx组（3.0年），YLL随着终生生存期的减少而增加（2.3、8.7、12.2年，分别）。平均终生医疗费用估计为30,857美元/患者。诊断后第一年，手术组的患者支付了更高的治疗费用，但每年的总体平均费用较低，为4359美元，而手术+ CTx / RTx组为7075美元，而CTx / RTx组为7626美元。肺癌导致整个患者失去大约10年的生命。损失与治疗方式有关，结果表明，在有生命的每年生存率和治疗成本方面，诊断出适合手术的低期疾病患者的肺癌有利于减轻疾病负担。